How effective is Roflumilast-DALIRESP Hong Kong version?

Roflumilast tablets (Roflumilast)-DALIRESP is a rare systemic anti-inflammatory oral drug in the current treatment of chronic obstructive pulmonary disease (COPD; COPD). The Hong Kong version of Roflumilast tablets has the same ingredients as the original drug in the European and American markets, and has clear clinical efficacy. It is mainly suitable for patients with moderate to severe COPD, especially those with chronic bronchitis as the main manifestation and frequent acute exacerbations. Roflumilast reduces lung inflammation and airway hyperresponsiveness by inhibiting the release of inflammatory mediators, thereby effectively reducing the number of acute exacerbations per year in COPD patients. Clinical studies have shown that long-term use of roflumilast can reduce the average annual acute exacerbation rate by about 17% and help improve lung function parameters such as FEV₁. Although it has limited effect on relieving acute dyspnea, it is excellent in long-term disease control.

Hong Kong versionDALIRESP is produced by the original pharmaceutical manufacturer, with stable quality and compliance with standards. It is regarded as an important part of the comprehensive management of COPD in Hong Kong medical care. In clinical practice, doctors usually judge whether roflumilast is suitable for use based on the patient's specific condition and previous attack history, and often use it in combination with inhaled bronchodilators or hormones to achieve synergistic effects. Some patients may experience side effects such as nausea, diarrhea, weight loss, or mild anxiety during the initial use. For this reason, a strategy of starting with 250 micrograms per day and then gradually transitioning to the standard dose of 500 micrograms is sometimes adopted to improve tolerance and reduce the risk of discontinuation.

Overall, the Hong Kong version of roflumilast tablets is considered to be an effective and effective COPD control drug suitable for long-term use in actual clinical applications.It is especially suitable for patients with repeated exacerbations and insufficient response to traditional treatments. With the deepening of understanding of the inflammatory mechanism of the disease, the role of roflumilast has gradually been recognized by more doctors, and it has become an important supplementary option for anti-inflammatory treatment of COPD in Hong Kong.

Reference materials:https://www.daliresp.com/